TD Cowen Reiterates Top Pick on Halozyme Therapeutics (HALO)

April 13, 2026 8:39 AM

TD Cowen analyst Brendan Smith reiterated a Buy rating and $96.00 price target on Halozyme Therapeutics (NASDAQ: HALO).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found